Ceftriaxone

證據等級: L5

預測適應症: 7 個

Ceftriaxone: From Serious Bacterial Infections to Infectious Otitis Media

One-Sentence Summary

Ceftriaxone is a third-generation cephalosporin antibiotic with well-established global use for serious bacterial infections including meningitis, sepsis, and pneumonia. The TxGNN model predicts it may be effective for Infectious Otitis Media, with 3 clinical trials and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Serious bacterial infections (3rd-generation cephalosporin)
Predicted New Indication	Infectious Otitis Media
TxGNN Prediction Score	99.26%
Evidence Level	L2
Italy Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this dataset. Based on known pharmacological information, ceftriaxone is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — particularly PBP2b and PBP2x — disrupting peptidoglycan cross-linking and causing bactericidal cell lysis. This mechanism confers broad-spectrum activity against both Gram-positive and Gram-negative pathogens.

The three primary organisms responsible for acute otitis media (AOM) — Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis — are all highly susceptible to ceftriaxone. Two RCTs (PMID 8989332, 11099083) have demonstrated its efficacy in treatment-refractory AOM, particularly when first-line oral antibiotics have failed. Its long elimination half-life (~8 hours) supports single-dose or short-course intramuscular regimens (IM 50 mg/kg/day), which is especially practical in paediatric settings where oral adherence is poor or rapid clinical response is needed.

The mechanistic connection is direct: ceftriaxone targets the causative pathogens of infectious otitis media through the same antibacterial mechanism that underpins its broader infectious disease use. Pharmacokinetic data show adequate drug penetration into middle ear fluid, providing further biological plausibility for the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01511107	Phase 2	Terminated	520	Randomised double-blind placebo-controlled trial comparing 5-day vs. 10-day antibiotic treatment for AOM in children aged 6–23 months — most directly relevant to antibiotic therapy duration in AOM; terminated early (reason not reported)
NCT02567825	NA	Completed	250	Tympanostomy tube placement vs. nonsurgical management for recurrent AOM — surgical RCT providing comparative framework and AOM burden data over 2 years
NCT01272999	N/A	Completed	391	Postmarketing observational study of Prevnar 13 impact on AOM incidence in children — confirms pneumococcal pathogen relevance in the AOM disease context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8989332	1997	RCT	Pediatrics	Prospective randomised single-blind trial: single-dose IM ceftriaxone vs. 10-day oral TMP-SMZ for AOM — ceftriaxone achieved comparable clinical efficacy
11099083	2000	RCT	Pediatric Infectious Disease Journal	1-day vs. 3-day IM ceftriaxone for non-responsive AOM in children — 3-day regimen demonstrated superior bacteriological and clinical outcomes
39361280	2024	Clinical Guideline	JAMA Network Open	Optimal paediatric outpatient antibiotic prescribing — 50% of US prescriptions deemed unnecessary; ceftriaxone endorsed as appropriate salvage choice for AOM
12166789	2002	Clinical Guideline	Clinical Pediatrics	Consensus recommendations for AOM management — ceftriaxone positioned as second-line agent when oral amoxicillin fails; provides prescribing decision criteria
35841649	2022	Retrospective Cohort	Int J Pediatric Otorhinolaryngology	Ceftriaxone IM use for AOM in a large US academic primary care population — characterises real-world utilisation factors including rising IM use for otitis-conjunctivitis
12237596	2002	Prospective Cohort	Pediatric Infectious Disease Journal	Nasopharyngeal carriage dynamics of S. pneumoniae after 3-day vs. 1-day IM ceftriaxone for non-responsive AOM — 3-day regimen better suppresses resistant strain carriage
20802367	2010	Review	Otology & Neurotology	Prevention and treatment of AOM and meningitis in children with cochlear implants — ceftriaxone identified as preferred IV/IM agent for invasive pneumococcal AOM
9877360	1998	Prospective	Pediatric Infectious Disease Journal	Bacteriological efficacy of 3-day IM ceftriaxone in non-responsive AOM — established pathogen eradication rates against drug-resistant S. pneumoniae
30279114	2019	Surveillance Study	Journal of Infection and Chemotherapy	Antimicrobial susceptibility of AOM pathogens in Japan (2014–2017) — resistance trend data informing which cases warrant ceftriaxone escalation
20660544	2010	Review	Pediatrics	Cochlear implant children: AOM and meningitis prevention and treatment guidelines — reinforces ceftriaxone as first-choice agent for complicated or invasive AOM

Italy Market Information

No marketing authorisations for Ceftriaxone were identified in the Italy (AIFA) regulatory database.

Note: Ceftriaxone is widely available internationally under brand names such as Rocephin and is included in the WHO Model List of Essential Medicines. The absence of records in this dataset is likely a data gap rather than actual unavailability in Italy.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two independent RCTs and multiple clinical guidelines have established intramuscular ceftriaxone as an effective second-line agent for treatment-refractory acute otitis media, with a clear and direct mechanistic basis targeting the primary causative pathogens.

To proceed, the following is needed:

Verify Italy (AIFA) regulatory status — absence of records likely reflects a data gap given ceftriaxone's global availability
Retrieve and review full package insert warnings and contraindications (flagged as Data Gap in this dataset)
Develop a paediatric dosing protocol with attention to neonatal safety given ceftriaxone's high protein binding (95–98%), which may displace bilirubin in neonates
Conduct an antimicrobial stewardship assessment — ceftriaxone is a WHO Access-group antibiotic; expansion into AOM should be restricted to treatment-failure cases to limit resistance pressure
Identify or commission a comparative RCT vs. high-dose amoxicillin in the European paediatric population to establish regional efficacy and formulary positioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.